Siglecs are widely expressed on leucocytes and bind to ubiquitously presented glycans
containing sialic acids (sialoglycans). Most Siglecs carry an immunoreceptor tyrosine‐based …

Simple Summary Hyperglycosylated cancer cells are often decorated with abundant sialic
acids, which are recognized by Sialic acid binding immunoglobulin type lectins (Siglecs) …

Abstract Changes in sialic acids in cancer have been observed for many years. In particular,
the increase of sialoglycan density or hypersialylation in tumors has been described. Recent …

Sialic acid sugar-carrying glycans, sialoglycans, are aberrantly expressed on many tumor
cells and have emerged as potent regulatory molecules involved in creating a tumor …

Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of receptors that
recognize sialoglycans–sialic acid containing glycans that are abundantly present on cell …

The overexpression of sialic acids on glycans, called hypersialylation, is a common
alteration found in cancer cells. Sialylated glycans can enhance immune evasion by …

Siglecs (sialic acid–binding immunoglobulin-like lectins) are a family of receptors that bind
sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in …

The sialic acid–binding immunoglobulin-like lectin (Siglec)–sialic acid immune axis is an
evolutionarily conserved immunoregulatory pathway that provides a mechanism for …

Upregulation of surface expressed sialoglycans on tumor cells is one of the mechanisms
which promote tumor growth and progression. Specifically, the interactions of sialic acids …

Siglecs are sialic acid-binding immunoglobulin-like lectins. Most Siglecs function as
transmembrane receptors mainly expressed on blood cells in a cell type-specific manner …